RE:RE:RE:RE:New Question - Restructuringdaveinmiss wrote: Thanks Health, Suitman, Shorting20...some good points. Yes, debt is a killer...the question in my view is whether the pipeline will produce winning/profitable drugs to service it and have some profit
That was the first question as well by an analyst on the conference call, because as you know investors have been tauted with their pipeline of 60 products and because they have no R&D and provide little visability on these new products it is believed that they are repacks or reformulations (when a drug is offered, say in a 200 mg dosage, instead of their current pill that is 150 mg and calling it a launch). Here is the part of the transcript that refers to your question and it appears like there are no drugs being launched in the near term -
which is the concern of investors...
Martin Landry
Hi. Good morning Allan and Ed. Thank you very much for the very comprehensive overview, that's helpful. One of my questions regards to your product development. You are mentioning that you have right now pipeline I think of 32 products. Can you talk about the timing of the launch of these products? Are these long-term projects over the next 10 years or there are like near-term - more near-term opportunities?
Allan Oberman
Good morning, Martin and thank you for your question. I purposely divided them into three buckets when I talked about them and you can look at those buckets relative to certain timeframes. The first 10 products that I described that have been approved or awaiting regulatory approval that will compete in markets that we estimate valued at $140 million. One can think of those in the more near-term versus medium or long-term.
With respect to the eight products that we anticipate will provide us certain first-to-market or early-to-market opportunities for some of them, we described those as products that we would envision coming to market in three to five years. And then finally with the remaining 14 products that we've begun to think about and begun to develop, one could anticipate those also in that three, four, five-year timeframe. None of our products at this particular moment have we thought out 10 years. So in total as you can see, we have 32 spread over let’s say the next five years.
\